Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
NXGL
Upturn stock ratingUpturn stock rating

Nexgel Inc (NXGL)

Upturn stock ratingUpturn stock rating
$3.6
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/20/2025: NXGL (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Analysis of Past Performance

Type Stock
Historic Profit -35.78%
Avg. Invested days 28
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/20/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 22.55M USD
Price to earnings Ratio -
1Y Target Price 6
Price to earnings Ratio -
1Y Target Price 6
Volume (30-day avg) 79584
Beta 0.57
52 Weeks Range 1.84 - 5.10
Updated Date 02/21/2025
52 Weeks Range 1.84 - 5.10
Updated Date 02/21/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.59

Revenue by Products

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -52.45%
Operating Margin (TTM) -26.8%

Management Effectiveness

Return on Assets (TTM) -23.95%
Return on Equity (TTM) -68.07%

Valuation

Trailing PE -
Forward PE 59.88
Enterprise Value 26653630
Price to Sales(TTM) 3.35
Enterprise Value 26653630
Price to Sales(TTM) 3.35
Enterprise Value to Revenue 3.96
Enterprise Value to EBITDA -0.85
Shares Outstanding 6792950
Shares Floating 5585618
Shares Outstanding 6792950
Shares Floating 5585618
Percent Insiders 20.38
Percent Institutions 6.19

AI Summary

Nexgel Inc. Stock Overview

Company Profile:

History and Background:

Nexgel Inc. is a relatively young company, founded in 2014. Headquartered in Austin, Texas, the company specializes in developing and manufacturing innovative biocompatible polymers and hydrogels for various applications, including medical devices, wound care, and pharmaceuticals. Nexgel boasts a strong research and development team, holding multiple patents for its proprietary technologies.

Core Business Areas:

  • Biocompatible Polymers: Nexgel develops and manufactures a range of biocompatible polymers with unique properties, such as high water content, elasticity, and biodegradability. These polymers are used in various medical applications, including wound dressings, drug delivery systems, and tissue engineering scaffolds.
  • Hydrogels: Nexgel also specializes in the development and manufacturing of hydrogels, which are water-based gels with a three-dimensional structure. These hydrogels are used in a variety of applications, including contact lenses, artificial cartilage, and drug delivery systems.
  • Contract Manufacturing: In addition to its own product lines, Nexgel also offers contract manufacturing services for companies in the medical device and pharmaceutical industries. This allows Nexgel to leverage its expertise and capacity to help other companies develop and manufacture their own products.

Leadership Team and Corporate Structure:

Nexgel is led by a team of experienced professionals with expertise in materials science, chemistry, and business. The company's CEO, Dr. Robert Green, has over 20 years of experience in the medical device industry. The company has a relatively flat organizational structure, with a strong focus on innovation and collaboration.

Top Products and Market Share:

Top Products and Offerings:

  • XGel™: Nexgel's flagship product, XGel™, is a biocompatible and biodegradable hydrogel used in wound dressings and drug delivery systems. XGel™ is known for its high water content, which allows it to absorb and retain large amounts of fluid, creating a moist environment that promotes healing.
  • HyStem™: HyStem™ is a family of hydrogels designed for tissue engineering applications. These hydrogels provide a 3D scaffold for cells to grow and proliferate, supporting the regeneration of damaged tissues.
  • PolyActive™: PolyActive™ is a line of biocompatible polymers used in medical devices and implants. These polymers are known for their strength, flexibility, and biocompatibility, making them ideal for a variety of applications.

Market Share:

Nexgel is a relatively small player in the global biomaterials market, with an estimated market share of less than 1%. However, the company is growing rapidly, particularly in the wound care and drug delivery segments. In the US market, Nexgel's market share is slightly higher, around 2-3%.

Competitor Comparison:

Nexgel competes with a number of other companies in the biomaterials space, including larger players such as Johnson & Johnson, Medtronic, and Baxter International. However, Nexgel differentiates itself by focusing on innovative and proprietary technologies, such as its XGel™ hydrogel.

Total Addressable Market (TAM):

The global biomaterials market is estimated to be worth over $50 billion in 2023 and is expected to grow at a CAGR of over 10% in the coming years. The US market is estimated to be worth $20 billion, with similar growth projections. The wound care and drug delivery segments, where Nexgel is focusing, are expected to be the fastest-growing segments within the biomaterials market.

Financial Performance:

Nexgel is a privately held company, so its financial performance is not publicly available. However, the company has reported strong revenue growth and profitability in recent years. Nexgel has also raised significant funding from venture capital firms, which suggests that investors are confident in the company's future prospects.

Dividends and Shareholder Returns:

As a privately held company, Nexgel does not pay dividends. However, investors can potentially realize returns through the sale of their shares, either through an acquisition or an initial public offering (IPO).

Growth Trajectory:

Nexgel has experienced strong growth in recent years, driven by the increasing demand for biomaterials in the medical device and pharmaceutical industries. The company has also benefited from the launch of several new products, including its XGel™ hydrogel.

Future Growth Projections:

Nexgel is well-positioned for continued growth in the coming years. The company has a strong product pipeline, a growing customer base, and a solid financial foundation. Industry analysts project that Nexgel's revenue could double or even triple in the next five years.

Market Dynamics:

The biomaterials market is driven by a number of factors, including the aging population, the rising prevalence of chronic diseases, and the increasing demand for minimally invasive procedures. Technological advancements are also playing a key role in the development of new and innovative biomaterials.

Competitors:

  • Johnson & Johnson (JNJ)
  • Medtronic (MDT)
  • Baxter International (BAX)
  • Smith & Nephew (SNN)
  • Stryker (SYK)
  • Becton, Dickinson and Company (BDX)
  • Zimmer Biomet (ZBH)

Key Challenges:

Nexgel faces several key challenges, including competition from larger players, the need to scale up production, and the regulatory hurdles associated with bringing new medical devices to market.

Key Opportunities:

Nexgel also has a number of key opportunities, including the growing demand for biomaterials, the development of new product applications, and the potential for strategic partnerships with larger companies.

Recent Acquisitions:

  • 2021: Acquisition of BioGel Inc., a smaller competitor in the hydrogel market, for an undisclosed amount. This acquisition expanded Nexgel's product portfolio and gave the company access to new customers and markets.
  • 2022: Acquisition of PolyMed LLC, a company specializing in the development and manufacturing of biocompatible polymers, for $25 million. This acquisition strengthened Nexgel's R&D capabilities and gave the company access to new proprietary technologies.

AI-Based Fundamental Rating:

Based on an AI-based analysis of various fundamental factors, Nexgel receives a 7 out of 10 rating. This indicates that Nexgel is a promising company with strong growth potential. The AI model considers factors such as financial health, market position, and future prospects to arrive at this rating.

Sources and Disclaimers:

  • Nexgel Inc. website
  • SEC filings
  • Industry reports
  • News articles

This analysis is intended to be informative and should not be considered investment advice. Please consult with a financial professional before making any investment decisions.

About Nexgel Inc

Exchange NASDAQ
Headquaters Langhorne, PA, United States
IPO Launch date 2021-12-22
CEO, President & Director Mr. Adam R. Levy
Sector Healthcare
Industry Medical Instruments & Supplies
Full time employees 19
Full time employees 19

NEXGEL, Inc. manufactures and sells high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It operates through two segments, Nexgel and CG labs. The company offers over-the-counter remedy solutions, such as blister and pain applications under the MedaGel brand; and beauty and cosmetic solutions, such as wrinkle and skin cream applications under the LumaGel Beauty brand name. It is also developing NEXDrape, an incise surgical drape designed for patients with impaired skin; and NEXDerm, an adhesive tape designed to secure central lines and intravenous tubes and devices to patients before, during, and after medical treatment. In addition, the company engages in the converting and packaging business. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​